Delcath Systems Inc DCTH
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Delcath Systems Reports Third Quarter 2026 Results and Business Highlights
Delcath Systems to Participate in Upcoming Investor Conferences
Delcath Systems to Host Third Quarter 2026 Earnings Call
Delcath Systems Highlights Clinical Program Presentations at ESMO Congress 2026 and Independent Data on Percutaneous Hepatic Perfusion in Liver-Dominant Metastatic Uveal Melanoma
Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Delcath Systems to Participate in Upcoming Investor Conferences
Trading Information
- Previous Close Price
- $14.93
- Day Range
- $17.51–20.30
- 52-Week Range
- $8.12–20.30
- Bid/Ask
- $19.73 / $20.12
- Shares Outstanding
- 34.79M
- Market Cap
- $703.34M
- Volume/Avg
- 3M / 464,446
Key Statistics
- Price/Earnings (Normalized)
- 2,027.00
- Price/Sales
- 7.37
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- 1.21%
Company Profile
Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.
- Sector
- Healthcare
- Industry
- Medical Devices
- Stock Style Box
- Small Growth
- Total Number of Employees
- 156
- Website
- https://www.delcath.com
Valuation
Metric | DCTH |
|---|---|
Price/Earnings (Normalized) | 2,027.00 |
Price/Book Value | 5.28 |
Price/Sales | 7.37 |
Price/Cash Flow | 33.39 |
Price/Earnings
DCTH
Financial Strength
Metric | DCTH |
|---|---|
Quick Ratio | 9.61 |
Current Ratio | 10.87 |
Interest Coverage | — |
Quick Ratio
DCTH
Profitability
Metric | DCTH |
|---|---|
Return on Assets (Normalized) | 15.74% |
Return on Equity (Normalized) | 17.48% |
Return on Invested Capital (Normalized) | 15.21% |
Return on Assets
DCTH
Medical Devices Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Abbott Laboratories ABT | LOCK|%<Gh@& | LOCK|<GY% | $191B | |||
| Medtronic PLC MDT | LOCK|>^qfxf | LOCK|z<y>! | $131B | |||
| Stryker Corp SYK | LOCK|&HlSg## | LOCK|%$J | $124B | |||
| Boston Scientific Corp BSX | LOCK|$$qrMLv | LOCK|^$lr | $64B | |||
| Edwards Lifesciences Corp EW | LOCK|%bJ!!Z@! | LOCK|^QX%W | $60B | |||
| GE HealthCare Technologies Inc Common Stock GEHC | LOCK|%%WGVQ> | LOCK|<@ | $38B | |||
| DexCom Inc DXCM | LOCK|sDb$^P>? | LOCK|qx&Dn | $30B | |||
| Koninklijke Philips NV ADR PHG | LOCK|V&< | LOCK|w<l | $30B | |||
| Steris PLC STE | LOCK|Vc@p>H@ | LOCK|JZ$^> | $25B | |||
| Zimmer Biomet Holdings Inc ZBH | LOCK|<XQTHsc | LOCK|kHK | $21B |
United States